Bio-Rad Laboratories reported net sales of $1,899.5 million for the first nine months of 2026, a slight increase from $1,890.0 million in 2025. Net income for the nine-month period rose significantly to $302.9 million compared to $39.9 million in the prior year, primarily driven by a $308.0 million gain from the change in fair market value of equity securities.
Bio-Rad Laboratories reported third-quarter 2026 financial results with net sales of $656.4 million, representing a 0.7% increase on a currency-neutral basis. The company returned to growth driven by the Clinical Diagnostics segment and Droplet Digital PCR instruments, despite ongoing challenges in the academic research market. GAAP net income was significantly impacted by a change in the fair market value of the company's investment in Sartorius AG.
Term
Q3 2026
“Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™ PCR instruments. Excluding restructuring and impairment items, margins expanded, reflecting benefits of our transformation initiatives. The reprioritization of our R&D efforts is yielding new, differentiated products for our customers, and our progress gives us confidence in our 2026 outlook.”
Norman Schwartz, Bio-Rad’s Chief Executive Officer